Redeye retains its positive view of Avensia following a solid Q3 report with a healthy underlying ma...
- FY sales SEK 2.1-2.2bn (prev. 2.4bn), EBITA margin 6% (prev.
- Weak on sales but higher gross margin - More restrucrings to come - Estimates likely up 5-10% on a...
- Pre-announces Q3 sales 5% below ABGSCe... - ... and ~7% below on adj.
- 9% organic growth (ABG 9%) and EBITA -6% vs ABG - Positive development in all markets, Systems gre...
- EBITA SEK 235m (+5% vs. ABG, +3% vs. IR consensus) - Medical Solutions +5% vs.
- Sales -6%, adj. EBITA +5% vs cons in Q3 - Strong performance in product companies behind solid mar...
- Sales -2%, adj. EBITA +1% vs. cons, +3% org. growth - Consensus to raise '24e-'25e EBITA by 1-3% -...
- Minor estimate revisions - Decline in utilisation appears to have stopped - '25e EV/EBITA of 8x H2...
- Both segments performed above our expectations in Q3 - EBIT up 2-1%, market to remain weak in H1'2...
- External manufacturing constinues to shine - We lower '24e-'26e EBITA by 2-1% - Share trading at 7...
- Q3 production much as expected - All share offer likely to be accepted - P/NAV of 1.
MoveByBike AB (”MoveByBike eller ”Koncernen”) fortsätter att utöka reklamintäkter genom ett nytt sam...
Aixia fortsätter att skörda framgångar inom AI och lanserar nya finansiella mål.
Cereno Scientific recently held a capital markets day (CMD), providing greater insight on its develo...
